The conundrum of diabetic neuropathies—past, present, and future

L Ang, K Mizokami-Stout, SA Eid, M Elafros… - Journal of Diabetes and …, 2022 - Elsevier
Diabetic neuropathy (DN) remains arguably the most prevalent chronic complication in
people with both type 1 and type 2 diabetes, including in youth, despite changes in the …

Pathophysiology and treatment of gastrointestinal motility disorders in the acutely ill

AM Deane, MJ Chapman… - Nutrition in Clinical …, 2019 - Wiley Online Library
Gastrointestinal dysmotility causes delayed gastric emptying, enteral feed intolerance, and
functional obstruction of the small and large intestine, the latter functional obstructions being …

The contemporary prevalence of diabetic neuropathy in type 1 diabetes: findings from the T1D exchange

KR Mizokami-Stout, Z Li, NC Foster, V Shah… - Diabetes …, 2020 - diabetesjournals.org
OBJECTIVE To evaluate the contemporary prevalence of diabetic peripheral neuropathy
(DPN) in participants with type 1 diabetes in the T1D Exchange Clinic Registry throughout …

Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady‐state concentrations

KL Jones, LQ Huynh, S Hatzinikolas… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aims To evaluate the effects of 8 weeks' administration of exenatide (EXE) once weekly on
gastric emptying of solids and liquids (using the “gold standard” technique, scintigraphy) …

Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes

KL Jones, RS Rigda, MDM Buttfield… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aim To evaluate the effects of the prandial glucagon‐like peptide‐1 receptor agonist
lixisenatide on gastric emptying and blood pressure (BP) and superior mesenteric artery …

Bariatric surgery induces a new gastric mucosa phenotype with increased functional glucagon-like peptide-1 expressing cells

L Ribeiro-Parenti, AC Jarry, JB Cavin… - Nature …, 2021 - nature.com
Abstract Glucagon-Like Peptide-1 (GLP-1) undergoes rapid inactivation by dipeptidyl
peptidase-4 (DPP4) suggesting that target receptors may be activated by locally produced …

Optimal measurement of gastric emptying of solids in gastroparesis or functional dyspepsia: evidence to establish standard test

M Camilleri, T Zheng, K Vosoughi, C Lupianez-Merly… - Gut, 2023 - gut.bmj.com
Objective Symptoms in gastroparesis (Gp) and functional dyspepsia (FD) overlap; using egg
protein substitute to measure gastric emptying of solids (GES),~ 40% of patients are …

Role of intestinal glucose absorption in glucose tolerance

T Wu, CK Rayner, KL Jones, C **e, C Marathe… - Current Opinion in …, 2020 - Elsevier
Intestinal glucose absorption is integral to postprandial glucose homeostasis. Glucose
absorption is dependent on a number of factors, including the exposure of carbohydrate to …

GLP-1 based therapies: clinical implications for gastroenterologists

MM Smits, DH van Raalte, L Tonneijck, MHA Muskiet… - Gut, 2016 - gut.bmj.com
The gut-derived incretin hormone, glucagon-like peptide 1 (GLP-1) lowers postprandial
blood glucose levels by stimulating insulin and inhibiting glucagon secretion. Two novel …

Scintigraphy of Gastrointestinal Motility: Best Practices in Assessment of Gastric and Bowel Transit in Adults

KP Banks, JW Revels, D Tafti, M Moshiri, N Shah… - …, 2024 - pubs.rsna.org
Various radiologic examinations and other diagnostic tools exist for evaluating
gastrointestinal diseases. When symptoms of gastrointestinal disease persist and no …